Lenalidomid Aristo

Lenalidomide, the active ingredient in Lenalidomid Aristo, is an immunomodulatory drug presented as a tablet for oral use. It is indicated for the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes, and mantle‑cell lymphoma, in adult patients. GNH USA supplies Lenalidomid Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomid Aristo (lenalidomide) is employed in hematologic malignancies and related disorders. - Multiple myeloma: helps control disease progression and improve survival. - Myelodysplastic syndromes: reduces transfusion dependence and delays transformation to acute leukemia. - Mantle‑cell lymphoma: contributes to tumor shrinkage and prolongs remission.

Lenalidomid Aristo may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools occurring intermittently. - Rash: skin redness or itching. - Nausea: feeling of sickness without vomiting. - Low blood counts: reduced neutrophils, platelets, or red cells. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe infections: opportunistic or bacterial infections requiring hospitalization. - Secondary malignancies: emergence of new cancers. - Hepatotoxicity: significant liver enzyme elevation. - Cardiac arrhythmias: irregular heart rhythms. - Pregnancy‑related teratogenicity: birth defects if exposure occurs during pregnancy.

Lenalidomid Aristo requires careful monitoring and patient education before and during therapy. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thrombosis prophylaxis: assess need for anticoagulation in high‑risk patients. - Renal function: adjust monitoring for patients with impaired kidney function. - Hepatic function: evaluate liver enzymes regularly. - Infection vigilance: monitor for signs of infection and manage promptly. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Lenalidomid Aristo can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin, DOACs): increased risk of bleeding. - Immunosuppressants (e.g., cyclosporine): heightened infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may modestly increase exposure. - NSAIDs: additive risk of gastrointestinal bleeding. - Vaccines: live vaccines should be avoided due to immunomodulation.